A proven foundation for vaccine protocols. Canine 1-DAPPv is a combination vaccine approved for protection against canine distemper virus, adenovirus type 1 and 2, canine parainfluenza virus, and canine parvovirus.
CANINE 1-DAPPV PROVIDES PROTECTION AGAINST:
Canine Distemper Virus, Canine Adenovirus 2, Canine Parainfluenza Virus, Canine Parvovirus (modified live viruses).
Protects against all known strains of CPV, including CPV-2c 2,3 High antigenic mass (titer), low passage parvovirus vaccine Canine vaccine containing CPV-2b, one of the most prevalent field strains of parvovirus Protects against 2 types of adenovirus that cause hepatitis and respiratory disease in dogs Provides disease coverage for commonly spread canine viruses, distemper, adenovirus types 1 and 2, parainfluenza and parvovirus in 1 formula First to publish data showing protection against CPV-2c challenge 2 Multiple studies demonstrate the ability to override maternal antibodies 1
An aid in the prevention of disease caused by canine distemper virus, adenovirus type 1 (hepatitis) and adenovirus type 2 (respiratory disease), canine parainfluenza virus, and canine parvovirus.
Recommended for use in healthy dogs 6 weeks of age or older.
ADMINISTRATION AND DOSAGE
Subcutaneous or intramuscular injection Primary vaccination may begin as early as 6 weeks Repeat at 2 to 4 week intervals until the dog is 12 weeks of age Annual revaccination with 1 dose is recommended Available in a 25 x 1 mL dose presentation
ALSO AVAILABLE IN OTHER FORMULATIONS
Efficacy & Comparisons
D–CANINE DISTEMPER VIRUS (CDV)
Onderstepoort-type strain in Nobivac
® vaccines provides a high level of safety 1 A–CANINE ADENOVIRUS TYPE 2 (CAV-2)
Protection against CAV-1 and CAV-2 without the side effects associated with modified live CAV-1 vaccines
4 P–CANINE PARAINFLUENZA VIRUS (CPIV)
Systemic administration stimulates a strong IgG response
PROVEN IN AN INDEPENDENT STUDY BY LARSON AND SCHULTZ
No clinical signs of disease were seen in Nobivac-vaccinated puppies after challenge with mixed CPV-2b and CPV-2c strains
2 First published data showing protection against CPV-2c challenge
2 All vaccinated puppies were protected from disease
All control puppies developed disease and 50% died or were euthanized
Professional Resources and Educational Materials
Keep your clinic and staff informed and aware of diseases and outbreaks.
In-depth information about canine vaccinations and veterinary best practices.
Use these ready-to-share posts to educate pet parents and drive business to your clinic for preventative care.
A handy guide to protect dogs and prevent the spread of leptospirosis.
1. Data on file, Merck Animal Health.
2. Larson LJ, Schultz RD. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant? Vet Ther. 2008;9(2):94–101.
3. Schultz RD, Thiel B, Mukhtar E, Sharp P, Larson LJ. Age and long-term protective immunity in dogs and cats. J Comp Pathol. 2010;142 Suppl 1:S102–S108.
4. Greene C, Rupprecht C. Rabies and other lyssavirus infections. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 3rd ed. St. Louis, MO: Saunders/Elsevier; 2006:167–183.
7. Cornell University College of Veterinary Medicine; American Association of Feline Practitioners. Feline leukemia virus. Available at: http://www.vet.cornell.edu/fhc/brochures/felv.html . Accessed December 29, 2011.
8. Spibey N, Greenwood NM, Sutton D, Chalmers WS, Tarpey I. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Vet Microbiol. 2008;128(1-2) :48-55.
View All Nobivac References